Project Grant R43CA254493

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $419,133.00 to the Massachusetts Institute of Technology (MIT) to develop an "ex vivo tumor biosensor" technology called AscitesPredict. The goal is to enable real-time evaluation of therapeutic sensitivities and cell identities from patient ascites (fluid accumulation) samples, which can be more readily obtained than traditional tumor biopsies. The...

This Project Grant award of $244,228 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports a research project at the University of Texas MD Anderson Cancer Center. The project aims to develop a functional proteomics approach to accurately map patient tumor samples to preclinical lung cancer models. Specifically, the researchers will: Expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using a reverse-phase protein...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...

This National Science Foundation Project Grant of $255,995 supported Encapsulate Inc. to develop an automated biochip platform for personalized cancer screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The award period was from May 15, 2022 to April 30, 2023. The platform will grow patient-derived cancer cells outside the body on biochips to screen them against chemotherapy drugs. This addresses the problem that over 70% of cancer patients undergo ineffective...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

This $1,213,619 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports Encapsulate Inc., a small disadvantaged business, in developing a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models. The goal is to create a rapid and accurate method for predicting the effectiveness of various cancer treatment options on individual patients, addressing a $2...

This $415,830 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an integrated nanoplasmonic sensing platform termed "Nano-CRISPR" for longitudinal tumor monitoring in ovarian cancer patients. The key products and services to be delivered include: Incorporation of single extracellular vesicle (EV) capture and analysis using plasmonic nanodisk arrays, CRISPR/Cas13a sensors for lysis-free,...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...

This Project Grant award from the National Science Foundation (NSF) under the Computer and Information Science and Engineering (CFDA 47.070) program provides $275,956 to develop an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimizations of their dosing. The project aims to create a generalized, self-dose-optimizing multi-sensor-integrated multi-organ-on-a-chip...